Neuropilin-1 (NRP1), implicated in various pro-tumorigenic processes, is a promising therapeutic target for cancer treatmentSecarna designed LNA-modified NRP1 specific antisense...
WOBURN, MA / ACCESSWIRE / November 3, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of...
LUND, SWEDEN / ACCESSWIRE / November 3, 2023 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Tumorad® in clinicJULY - SEPTEMBER IN BRIEFNet sales...
Potential to address cancer treatment related Cytokine Release SyndromeLONDON, UK / ACCESSWIRE / November 3, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF),...
Five rusfertide abstracts accepted for oral and poster presentations at the 65th ASH Annual Meeting and Exposition (ASH2023)Positive topline results...
Two oral presentations and three poster presentations elucidate new data relevant to rusfertide, a hepcidin mimetic with potential therapeutic value...
Quadri Pharma will cover 50% of the costs of development activity up to a capped dollar contributionJaguar to host virtual...
Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billionSpikevax U.S. market share to...
Planegg/Martinsried, November 4, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the...
The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate innate immune...
Data further characterize the mechanism for Gamida Cell’s proprietary nicotinamide (NAM) technology’s expansion and enhancement of cellsBOSTON, Nov. 04, 2023...
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patientsWOBURN, Mass.,...
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer...
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated...
– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages...
WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology...
Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across heterogeneous EGFR mutation subtypes No new safety...
— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1...
Panelists of Thrive 365 with MHTC Members (From Left) Ms. Lily Jasmin, Vice President of Corporate Strategy; Ms. Norhaslina Mamat,...
In a 100-patient study of Mia there were no reports of capsular contracture or rupture. The new Zensor™ RFID platform...